Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clopidogrel and aspirin

This article was originally published in The Tan Sheet

Executive Summary

Bristol-Myers Squibb/Sanofi-Synthelabo's Plavix antiplatelet agent has additional benefits when combined with aspirin in patients with acute coronary syndromes, researchers report in Aug. 16 NEJM. Salim Yusuf, PhD, McMaster University, et al., report death from cardiovascular causes, nonfatal MI or stroke occurred in 9.3% of patients taking clopidogrel and aspirin, compared with 11.4% death rate in patients taking placebo and aspirin. Although major bleeding was significantly more common in clopidogrel group (3.7% vs. 2.7% in placebo arm), Yusuf et al. say excess risk of bleeding "is similar to that observed with aspirin alone." Randomized, double-blind, placebo-controlled study assigned 12,562 patients to either 75 mg/day clopidogrel or placebo, in addition to 75 mg-325 mg aspirin daily
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel